Europe Lung Cancer Therapy Market Forecast to 2030

Europe Lung Cancer Therapy Market Forecast to 2030 – Regional Analysis – By Therapy Type (Noninvasive and Minimally Invasive), Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), and End User (Hospitals, Oncology Clinics, Research Centers, and Others)

Send Enquiry
Item ID: BMIRE00029871 Category: Tag:

$2,840$4,440

Description

The Europe lung cancer therapy market was valued at US$ 9,919.66 million in 2022 and is expected to reach US$ 25,548.74 million by 2030; it is estimated to grow at a CAGR of 12.6% from 2022 to 2030.

Government Initiatives for Screening and Treatment of Lung Cancer Drive Europe Lung Cancer Therapy Market

According to an article published by Johnson & Johnson, lung cancer is a leading cause of cancer mortality in the world, and it is generally detected in the later stages. In the initial stages, people with lung cancer show no prominent symptoms, and therefore, in almost 50% of the detected cases, cancer has already reached the metastasis stage. In response to the seriousness of this condition, governments of various countries are focusing on introducing initiatives for encouraging early detection and screening, followed by providing early treatment for lung cancer. The Beating Cancer Plan introduced by the European Health Union aims to tackle the entire disease pathway by focusing on prevention, treatment, and care of lung cancer patients. Thus, an upsurge in initiatives taken by governments for the early detection and proper treatment of lung cancer patients fuels the growth of the Europe lung cancer therapy market.

Europe Lung Cancer Therapy Market Overview

According to an article titled “Lung Cancer in Germany,” published in the Journal of Thoracic Oncology in June 2022, cancer is among the second most frequent cause of death in Germany, accounting for 25% of all deaths. With an age-standardized incidence rate of 52.1% and 32.7% (per 100,000) in men and women, respectively, lung cancer ranks second in men and third in women (accounting for 13.3% and 9.4% of all newly diagnosed cancers, respectively). The average age of cancer diagnosis is 70 years (men) and 69 years (women); 52% of all patients present with stage IV. The incidence rates in women and men have converged since the 1990s because of long-term changes in smoking habits. Currently, every fourth man (27.0%) and every fifth woman (20.8%) in Germany smokes regularly.

The German National Cancer Plan designates organ cancer centers (lung cancer centers), oncology centers, and comprehensive cancer centers to offer general oncologic care in Germany. As of 2020, 64 lung cancer centers at 79 institutions were certified nationwide. Rise in the incidence of lung cancer and an increase in the number of lung cancer centers across Germany are fueling the growth of the market.

Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Million)

Europe Lung Cancer Therapy Market Segmentation

The Europe lung cancer therapy market is segmented based on therapy type, indication, end user, and country.

Based on therapy type, the Europe lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held a larger share in 2022. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.

By indication, the Europe lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held a larger share in 2022.

By end user, the Europe lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held the largest share in 2022.

Based on country, the Europe lung cancer therapy market is segmented into Germany, the UK, France, Italy, Spain, Russia, and the Rest of Europe. Germany dominated the Europe lung cancer therapy market in 2022.

Medtronic Plc, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Olympus Corp, Meiji Seika Pharma Co Ltd, and Advanz Pharma Corp are some of the leading companies operating in the Europe lung cancer therapy market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

Year of Publication:

At 12.6% CAGR, the Europe Lung Cancer Therapy Market is Speculated to be Worth US$ 25,548.74 Million by 2030, Says the Research Team

According to the Research Team’ research, the Europe lung cancer therapy market was valued at US$ 9,919.66 million in 2022 and is expected to reach US$ 25,548.74 million by 2030, registering a CAGR of 12.6% from 2022 to 2030. Increase in cases of lung cancer and government initiatives for screening and treatment of lung cancer are among the critical factors attributed to the Europe lung cancer therapy market expansion.

Lung cancer is among the main causes of mortality across the world. This type of cancer can be treated more effectively if it is diagnosed early. Therefore, people at a high risk of lung cancer need to undergo routine testing to detect the formation of cancerous growth inside their lungs. Globally lung cancer is the most common cancer in men and the second most common cancer in women. According to the World Health Organization (WHO), lung cancer is the leading cause of cancer-related deaths globally, in both men and women. As per the World Cancer Research Fund International, ~2.2 million new lung cancer cases were registered worldwide in 2020. Lung cancer is among one of the main causes of mortality across the world. Lung cancer screening is a critical component of cancer prevention approaches. The prognosis of lung cancer patients is better when the disease is diagnosed early, so people at high risk of lung cancer are prompted to undergo routine checkups to detect the formation of cancerous growth in their lungs. As per research conducted by the cancer journal Annals of Oncology, around 1,261,990 cancer patients are expected to die in 2023 in the EU region. Lung cancer death rates would increase by over 1% to 13.6 per 100,000. As more UK women started smoking earlier than those in the EU, there will be a 13.8% decrease in the death rate from lung cancer among women in the UK, although the death rate of 16.2 per 100,000 is still higher than among women in the EU. In the UK, lung cancer currently claims more per 100,000 than breast cancer, which claims 13.5 per 100,000. When the researchers particularly examined lung cancer death rates in five EU nations in addition to the UK, they discovered that while rates are expected to decline for men in the most populous six nations (France, Germany, Italy, Poland, and Spain), they will increase for women in France, Italy, and Spain by about 14%, 5.6%, and 5%, respectively. The researchers discovered that among women in various age groups, expected mortality rates from lung cancer decreased among those between the ages of 25 and 64 but increased among those between the ages of 65 and over 75, leading to an increase overall. Additionally, according to the National Center for Biotechnology Information (NCBI), ~41,000 new diagnoses of lung cancers and ~34,000 deaths are recorded yearly in Italy. Also, Data provided by the Health Ministry of Turkey states that ~23,000 men and ~4,500 women are diagnosed with lung cancer annually in Turkey. Thus, the rising incidence of lung cancer worldwide is contributing to the research and development activities for lung cancer therapy, which is, in turn, driving the market growth.

On the contrary, high cost of lung cancer therapy hampers the growth of Europe lung cancer therapy market.

Based on therapy type, the Europe lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held 70.5% share of the Europe lung cancer therapy market in 2022, amassing US$ 6,998.31 million. It is projected to garner US$ 17,453.17 million by 2030 to expand at 12.1% CAGR during 2022-2030. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.

By indication, the Europe lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held 87.5% share of the Europe lung cancer therapy market in 2022, amassing US$ 8,683.40 million. It is projected to garner US$ 22,869.09 million by 2030 to expand at 12.9% CAGR during 2022-2030.

By end user, the Europe lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held 45.0% share of the Europe lung cancer therapy market in 2022, amassing US 4,466.78 million. It is projected to garner US$ 11,187.75 million by 2030 to expand at 12.2% CAGR during 2022-2030.

Based on country, the Europe lung cancer therapy market is segmented into Germany, the UK, France, Italy, Spain, Russia, and the Rest of Europe. Germany held 29.6% share of Europe lung cancer therapy market in 2022, amassing US$ 2,936.22 million. It is projected to garner US$ 7,378.48 million by 2030 to expand at 12.2% CAGR during 2022-2030.

Key players operating in the Europe lung cancer therapy market are Medtronic Plc, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Olympus Corp, Meiji Seika Pharma Co Ltd, and Advanz Pharma Corp, among others.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe lung cancer therapy market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in Europe lung cancer therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the lung cancer therapy market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution

TABLE OF CONTENTS

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Europe Lung Cancer Therapy Market, by Country
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Lung Cancer Therapy Market – Key Industry Dynamics
4.1 Market Drivers:
4.1.1 Increase in Cases of Lung Cancer
4.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
4.2 Market Restraints
4.2.1 High Cost of Lung Cancer Therapy
4.3 Market Opportunities
4.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
4.4 Future Trends
4.4.1 Growing Demand for Targeted Therapy
4.5 Impact Analysis:
5. Lung Cancer Therapy Market – Europe Market Analysis
5.1 Europe Lung Cancer Therapy Market Revenue (US$ Mn), 2020 – 2030
6. Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by Therapy Type
6.1 Overview
6.2 Europe Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
6.3 Non-Invasive Therapy
6.3.1 Overview
6.3.2 Non-Invasive Therapy: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Minimally Invasive
6.4.1 Overview
6.4.2 Minimally Invasive: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
6.4.3 Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
7. Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by Indication
7.1 Overview
7.2 Europe Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer
7.3.1 Overview
7.3.2 Non-Small Cell Lung Cancer: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Small Cell Lung Cancer
7.4.1 Overview
7.4.2 Small Cell Lung Cancer: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8. Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by End User
8.1 Overview
8.2 Europe Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
8.3 Hospitals
8.3.1 Overview
8.3.2 Hospitals: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Oncology Clinics
8.4.1 Overview
8.4.2 Oncology Clinics: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Research Centers
8.5.1 Overview
8.5.2 Research Centers: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9. Europe Lung Cancer Therapy Market – Country Analysis
9.1.1 Europe Lung Cancer Therapy Market, by Country
9.1.1.1 UK
9.1.1.1.1 Overview
9.1.1.1.2 UK: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.1.3 UK: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.1.3.1 UK: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.1.4 UK: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.1.5 UK: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.2 Germany
9.1.1.2.1 Overview
9.1.1.2.2 Germany: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.2.3 Germany: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.2.3.1 Germany: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.2.4 Germany: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.2.5 Germany: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.3 France
9.1.1.3.1 Overview
9.1.1.3.2 France: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.3.3 France: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.3.3.1 France: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.3.4 France: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.3.5 France: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.4 Italy
9.1.1.4.1 Overview
9.1.1.4.2 Italy: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.4.3 Italy: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.4.3.1 Italy: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.4.4 Italy: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.4.5 Italy: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.5 Spain
9.1.1.5.1 Overview
9.1.1.5.2 Spain: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.5.3 Spain: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.5.3.1 Spain: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.5.4 Spain: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.5.5 Spain: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.6 Russia
9.1.1.6.1 Overview
9.1.1.6.2 Russia: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.6.3 Russia: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.6.3.1 Russia: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.6.4 Russia: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.6.5 Russia: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
9.1.1.7 Rest of Europe
9.1.1.7.1 Overview
9.1.1.7.2 Rest of Europe: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.7.3 Rest of Europe: Europe Lung Cancer Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.7.3.1 Rest of Europe: Europe Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)
9.1.1.7.4 Rest of Europe: Europe Lung Cancer Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.7.5 Rest of Europe: Europe Lung Cancer Therapy Market, by End User, 2020-2030 (US$ Million)
10. Lung Cancer Therapy Market – Industry Landscape
10.1 Overview
10.2 Growth Strategies in Europe Lung Cancer Therapy Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Medtronic Plc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 RF Medical Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Johnson & Johnson
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Merck KGaA
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Sun Pharmaceutical Industries Ltd
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Bioventus Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Olympus Corp
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Meiji Seika Pharma Co Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Advanz Pharma Corp
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms

LIST OF TABLES

Table 1. Europe Lung Cancer Therapy Market Segmentation
Table 2. Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 3. UK: Europe Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 4. UK: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 5. UK: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 6. UK: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 7. Germany: Europe Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 8. Germany: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 9. Germany: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 10. Germany: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 11. France: Europe Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 12. France: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 13. France: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 14. France Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 15. Italy Europe Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 16. Italy: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 17. Italy: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 18. Italy: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 19. Spain: Europe Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 20. Spain: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 21. Spain: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 22. Spain: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 23. Russia: Europe Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 24. Russia: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 25. Russia: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 26. Russia: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 27. Rest of Europe: Europe Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 28. Rest of Europe: Europe Lung Cancer Therapy Market, by Minimally Invasive- Revenue and Forecast to 2030 (US$ Million)
Table 29. Rest of Europe: Europe Lung Cancer Therapy Market, by Indication- Revenue and Forecast to 2030 (US$ Million)
Table 30. Rest of Europe: Europe Lung Cancer Therapy Market, by End User- Revenue and Forecast to 2030 (US$ Million)
Table 31. Recent Inorganic Growth Strategies in the Europe Lung Cancer Therapy Market
Table 32. Recent Organic Growth Strategies in Europe Lung Cancer Therapy Market
Table 33. Glossary of Terms, Europe Lung Cancer Therapy Market

LIST OF FIGURES

Figure 1. Europe Lung Cancer Therapy Market Segmentation, By Country
Figure 2. Europe Lung Cancer Therapy Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Lung Cancer Therapy Market Revenue (US$ Mn), 2020 – 2030
Figure 5. Europe Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
Figure 6. Non-Invasive Therapy: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Minimally Invasive: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Europe Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 9. Non-Small Cell Lung Cancer: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Small Cell Lung Cancer: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Europe Lung Cancer Therapy Market Revenue Share, End User, 2022 & 2030 (%)
Figure 12. Hospitals: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Oncology Clinics: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Research Centers: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Europe Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Europe Lung Cancer Therapy Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 17. Europe Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 18. UK: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Germany: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. France: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Italy: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Spain: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Russia: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Rest of Europe: Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Growth Strategies in Europe Lung Cancer Therapy Market

The List of Companies – Europe Lung Cancer Therapy Market

1. Advanz Pharma Corp
2. Bioventus Inc
3. Johnson & Johnson
4. Medtronic Plc
5. Meiji Seika Pharma Co Ltd
6. Merck KGaA
7. Olympus Corp
8. RF Medical Co Ltd
9. Sun Pharmaceutical Industries Ltd

Reviews

There are no reviews yet.

Be the first to review “Europe Lung Cancer Therapy Market Forecast to 2030”